CLARITY
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Uveitis
Study Purpose
The purpose of this clinical research study is to learn more about the use of an investigational medicine, called brepocitinib, for the treatment of active non-infectious intermediate-, posterior- or pan-uveitis, or NIU (non-infectious uveitis) for short. Brepocitinib (“study drug”) works by decreasing inflammation. This study is being done to determine how safe and effective brepocitinib is and if it works to help decrease the inflammation associated with NIU and will monitor the long-term safety of brepocitinib when taken for a period up to 96 weeks.
Who Can Participate
Age: 18-75 years old
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00002288
- StudyID: 2024-01524
- ClinicalTrials.gov: NCT06431373
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422